{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T18:27:01Z","timestamp":1784140021794,"version":"3.55.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T00:00:00Z","timestamp":1609977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R21 CA170375"],"award-info":[{"award-number":["R21 CA170375"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R25-CA153825"],"award-info":[{"award-number":["R25-CA153825"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI P30 CA118100"],"award-info":[{"award-number":["NCI P30 CA118100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["NCI P30 CA118100"],"award-info":[{"award-number":["NCI P30 CA118100"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["R21 TR001731-01"],"award-info":[{"award-number":["R21 TR001731-01"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["OC110514 W81XWH-11-OCRP-TEA"],"award-info":[{"award-number":["OC110514 W81XWH-11-OCRP-TEA"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000057","name":"National Institute of General Medical Sciences","doi-asserted-by":"publisher","award":["P50 GM085273"],"award-info":[{"award-number":["P50 GM085273"]}],"id":[{"id":"10.13039\/100000057","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000097","name":"National Center for Research Resources","doi-asserted-by":"publisher","award":["5P20RR016480"],"award-info":[{"award-number":["5P20RR016480"]}],"id":[{"id":"10.13039\/100000097","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Rho-family GTPases, including Ras-related C3 botulinum toxin substrate 1 (Rac1) and cell division control protein 42 (Cdc42), are important modulators of cancer-relevant cell functions and are viewed as promising therapeutic targets. Based on high-throughput screening and cheminformatics we identified the R-enantiomer of an FDA-approved drug (ketorolac) as an inhibitor of Rac1 and Cdc42. The corresponding S-enantiomer is a non-steroidal anti-inflammatory drug (NSAID) with selective activity against cyclooxygenases. We reported previously that R-ketorolac, but not the S-enantiomer, inhibited Rac1 and Cdc42-dependent downstream signaling, growth factor stimulated actin cytoskeleton rearrangements, cell adhesion, migration and invasion in ovarian cancer cell lines and patient-derived tumor cells.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this study we treated mice with R-ketorolac and measured engraftment of tumor cells to the omentum, tumor burden, and target GTPase activity. In order to gain insights into the actions of R-ketorolac, we also performed global RNA-sequencing (RNA-seq) analysis on tumor samples.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Treatment of mice with R-ketorolac decreased omental engraftment of ovarian tumor cells at 18\u2009h post tumor cell injection and tumor burden after 2\u2009weeks of tumor growth. R-ketorolac treatment inhibited tumor Rac1 and Cdc42 activity with little impact on mRNA or protein expression of these GTPase targets. RNA-seq analysis revealed that R-ketorolac decreased expression of genes in the HIF-1 signaling pathway. R-ketorolac treatment also reduced expression of additional genes associated with poor prognosis in ovarian cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>These findings suggest that R-ketorolac may represent a novel therapeutic approach for ovarian cancer based on its pharmacologic activity as a Rac1 and Cdc42 inhibitor. R-ketorolac modulates relevant pathways and genes associated with disease progression and worse outcome.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-07716-1","type":"journal-article","created":{"date-parts":[[2021,1,7]],"date-time":"2021-01-07T17:03:50Z","timestamp":1610039030000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["The R-enantiomer of ketorolac reduces ovarian cancer tumor burden in vivo"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2745-550X","authenticated-orcid":false,"given":"Martha M.","family":"Grimes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Ray","family":"Kenney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayna R.","family":"Dominguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn J.","family":"Brayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Wandinger-Ness","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie G.","family":"Hudson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,7]]},"reference":[{"issue":"1","key":"7716_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21442","volume":"68","author":"RL Siegel","year":"2018","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7\u201330 [cited 2019 Jan 17]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.3322\/caac.21442.","journal-title":"CA Cancer J Clin"},{"issue":"9951","key":"7716_CR2","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1016\/S0140-6736(13)62146-7","volume":"384","author":"GC Jayson","year":"2014","unstructured":"Jayson GC, Kohn EC, Kitchener HC, Ledermann JA. Ovarian cancer. Lancet. 2014;384(9951):1376\u201388 [cited 2019 Jan 17]. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0140673613621467.","journal-title":"Lancet"},{"issue":"suppl_8","key":"7716_CR3","doi-asserted-by":"publisher","first-page":"viii13","DOI":"10.1093\/annonc\/mdx446","volume":"28","author":"EL Christie","year":"2017","unstructured":"Christie EL, DDL B. Acquired chemotherapy resistance in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii13\u20135 [cited 2019 Jan 29]. Available from: https:\/\/academic.oup.com\/annonc\/article\/28\/suppl_8\/viii13\/4693812.","journal-title":"Ann Oncol"},{"issue":"10","key":"7716_CR4","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1038\/nrc3144","volume":"11","author":"S Vaughan","year":"2011","unstructured":"Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking Ovarian Cancer: Recommendations for Improving Outcomes. Nat Rev Cancer. 2011;11(10):719\u201325 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3380637\/.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"7716_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s12032-017-0960-z","volume":"34","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum-resistant\u2013platinum-refractory ovarian cancer. Med Oncol. 2017;34(6):103 [cited 2019 Jan 17]. Available from. https:\/\/doi.org\/10.1007\/s12032-017-0960-z.","journal-title":"Med Oncol"},{"key":"7716_CR6","doi-asserted-by":"crossref","unstructured":"DiSilvestro P, Secord AA. Maintenance treatment of recurrent ovarian cancer: Is it ready for prime time? Cancer Treat Rev. 2018;69:53\u201365 [cited 2019 Mar 1]. Available from: https:\/\/www.cancertreatmentreviews.com\/article\/S0305-7372(18)30095-1\/abstract.","DOI":"10.1016\/j.ctrv.2018.06.001"},{"issue":"8","key":"7716_CR7","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1038\/nrm.2016.67","volume":"17","author":"RG Hodge","year":"2016","unstructured":"Hodge RG, Ridley AJ. Regulating Rho GTPases and their regulators. Nat Rev Mol Cell Biol. 2016;17(8):496\u2013510 [cited 2019 Jan 17]. Available from: https:\/\/www.nature.com\/articles\/nrm.2016.67.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"9","key":"7716_CR8","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1517\/17460441.2015.1058775","volume":"10","author":"Y Lin","year":"2015","unstructured":"Lin Y, Zheng Y. Approaches of targeting Rho GTPases in cancer drug discovery. Expert Opin Drug Discov. 2015;10(9):991\u20131010 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4824952\/.","journal-title":"Expert Opin Drug Discov"},{"key":"7716_CR9","doi-asserted-by":"crossref","unstructured":"Orgaz JL, Herraiz C, Sanz-Moreno V. Rho GTPases modulate malignant transformation of tumor cells. Small GTPases. 2014;5 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4125382\/.","DOI":"10.4161\/sgtp.29019"},{"issue":"2","key":"7716_CR10","doi-asserted-by":"publisher","first-page":"123","DOI":"10.4161\/21541248.2014.973749","volume":"6","author":"M Pajic","year":"2015","unstructured":"Pajic M, Herrmann D, Vennin C, Conway JR, Chin VT, Johnsson A-KE, et al. The dynamics of Rho GTPase signaling and implications for targeting cancer and the tumor microenvironment. Small GTPases. 2015;6(2):123\u201333 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4601362\/.","journal-title":"Small GTPases"},{"issue":"23","key":"7716_CR11","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1038\/onc.2016.473","volume":"36","author":"I Zandvakili","year":"2017","unstructured":"Zandvakili I, Lin Y, Morris JC, Zheng Y. Rho GTPases: Anti- or Pro-neoplastic Targets? Oncogene. 2017;36(23):3213\u201322 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5464989\/.","journal-title":"Oncogene"},{"issue":"3","key":"7716_CR12","doi-asserted-by":"publisher","first-page":"159","DOI":"10.4161\/sgtp.26530","volume":"4","author":"JK Alan","year":"2013","unstructured":"Alan JK, Lundquist EA. Mutationally activated Rho GTPases in cancer. Small GTPases. 2013;4(3):159\u201363 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3976972\/.","journal-title":"Small GTPases"},{"issue":"11","key":"7716_CR13","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1016\/j.ejca.2014.04.019","volume":"50","author":"V Alonso-Espinaco","year":"2014","unstructured":"Alonso-Espinaco V, Cuatrecasas M, Alonso V, Escudero P, Marmol M, Horndler C, et al. RAC1b overexpression correlates with poor prognosis in KRAS\/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX\/XELOX chemotherapy. Eur J Cancer Oxf Engl. 2014;50(11):1973\u201381.","journal-title":"Eur J Cancer Oxf Engl"},{"key":"#cr-split#-7716_CR14.1","doi-asserted-by":"crossref","unstructured":"Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: An Emerging Therapeutic Option for Targeting Cancer Angiogenesis and Metastasis. Mol Cancer Ther. 2013;12","DOI":"10.1158\/1535-7163.MCT-13-0164"},{"key":"#cr-split#-7716_CR14.2","unstructured":"(10) [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3823055\/."},{"issue":"4","key":"7716_CR15","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.3892\/ijo.2017.4093","volume":"51","author":"GA Cardama","year":"2017","unstructured":"Cardama GA, Gonzalez N, Maggio J, Menna PL, Gomez DE. Rho GTPases as therapeutic targets in cancer (Review). Int J Oncol. 2017;51(4):1025\u201334 [cited 2019 Jan 29]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5592879\/.","journal-title":"Int J Oncol"},{"issue":"6","key":"7716_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1038\/sj.bjc.6600510","volume":"87","author":"G Fritz","year":"2002","unstructured":"Fritz G, Brachetti C, Bahlmann F, Schmidt M, Kaina B. Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer. 2002;87(6):635\u201344 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2364248\/.","journal-title":"Br J Cancer"},{"issue":"10","key":"7716_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/cancers10100358","volume":"10","author":"LG Hudson","year":"2018","unstructured":"Hudson LG, Gillette JM, Kang H, Rivera MR, Wandinger-Ness A. Ovarian Tumor Microenvironment Signaling: Convergence on the Rac1 GTPase. Cancers. 2018;10(10):358 [cited 2019 Jan 29]. Available from: https:\/\/www.mdpi.com\/2072-6694\/10\/10\/358.","journal-title":"Cancers"},{"issue":"2","key":"7716_CR18","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1083\/jcb.201612069","volume":"217","author":"CD Lawson","year":"2018","unstructured":"Lawson CD, Ridley AJ. Rho GTPase signaling complexes in cell migration and invasion. J Cell Biol. 2018;217(2):447\u201357 [cited 2019 Jan 29]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5800797\/.","journal-title":"J Cell Biol"},{"issue":"2","key":"7716_CR19","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1007\/s12032-014-0329-5","volume":"32","author":"R Leng","year":"2015","unstructured":"Leng R, Liao G, Wang H, Kuang J, Tang L. Rac1 expression in epithelial ovarian cancer: effect on cell EMT and clinical outcome. Med Oncol. 2015;32(2):28 [cited 2019 Jan 17]. Available from. https:\/\/doi.org\/10.1007\/s12032-014-0329-5.","journal-title":"Med Oncol"},{"issue":"4","key":"7716_CR20","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12032-013-0689-2","volume":"30","author":"Q Yang","year":"2013","unstructured":"Yang Q, Luo G-Y, Li Y, Shan H-B, Wang H-Y, Xu G-L. Expression of Rac-1 related to tumor depth, lymph node metastasis and patient prognosis in esophageal squamous cell carcinoma. Med Oncol. 2013;30(4):689 [cited 2019 Jan 17]. Available from. https:\/\/doi.org\/10.1007\/s12032-013-0689-2.","journal-title":"Med Oncol"},{"issue":"8","key":"7716_CR21","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1158\/1541-7786.MCR-17-0053","volume":"15","author":"C Yoon","year":"2017","unstructured":"Yoon C, Cho S-J, Chang KK, Park DJ, Ryeom SW, Yoon SS. Role of Rac1 pathway in epithelial-to-mesenchymal transition and cancer stem-like cell phenotypes in gastric adenocarcinoma. Mol Cancer Res MCR. 2017;15(8):1106\u201316 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5540756\/.","journal-title":"Mol Cancer Res MCR"},{"issue":"14","key":"7716_CR22","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.7150\/jca.16198","volume":"7","author":"Y Zhou","year":"2016","unstructured":"Zhou Y, Liao Q, Han Y, Chen J, Liu Z, Ling H, et al. Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer. J Cancer. 2016;7(14):2100\u20139 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5118674\/.","journal-title":"J Cancer"},{"issue":"22","key":"7716_CR23","doi-asserted-by":"publisher","first-page":"5064","DOI":"10.1158\/1078-0432.CCR-15-0461","volume":"21","author":"Y Guo","year":"2015","unstructured":"Guo Y, Kenney SR, Cook L, Adams SF, Rutledge T, Romero E, et al. A novel pharmacologic activity of ketorolac for therapeutic benefit in ovarian cancer patients. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(22):5064\u201372 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4644688\/.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"7716_CR24","doi-asserted-by":"crossref","unstructured":"Jansen S, Gosens R, Wieland T, Schmidt M. Paving the Rho in cancer metastasis: Rho GTPases and beyond. Pharmacol Ther. 2018;183:1\u201321 [cited 2019 Mar 1]. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S016372581730236X.","DOI":"10.1016\/j.pharmthera.2017.09.002"},{"key":"#cr-split#-7716_CR25.1","doi-asserted-by":"crossref","unstructured":"Smithers CC, Overduin M. Structural Mechanisms and Drug Discovery Prospects of Rho GTPases. Cells. 2016;5","DOI":"10.3390\/cells5020026"},{"key":"#cr-split#-7716_CR25.2","unstructured":"(2) [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4931675\/."},{"issue":"11","key":"7716_CR26","doi-asserted-by":"publisher","first-page":"e0142182","DOI":"10.1371\/journal.pone.0142182","volume":"10","author":"TI Oprea","year":"2015","unstructured":"Oprea TI, Sklar LA, Agola JO, Guo Y, Silberberg M, Roxby J, et al. Novel Activities of Select NSAID R-Enantiomers against Rac1 and Cdc42 GTPases. PLOS ONE. 2015;10(11):e0142182 [cited 2017 Mar 29]. Available from: http:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0142182.","journal-title":"PLOS ONE"},{"issue":"10","key":"7716_CR27","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-15-0419","volume":"14","author":"Y Guo","year":"2015","unstructured":"Guo Y, Kenney SR, Muller CY, Adams S, Rutledge T, Romero E, et al. R-Ketorolac Targets Cdc42 and Rac1 and Alters Ovarian Cancer Cell Behaviors Critical for Invasion and Metastasis. Mol Cancer Ther. 2015;14(10):2215\u201327 [cited 2017 Mar 29]. Available from: http:\/\/mct.aacrjournals.org\/content\/14\/10\/2215.","journal-title":"Mol Cancer Ther"},{"issue":"6","key":"7716_CR28","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/j.1552-4604.1996.tb05042.x","volume":"36","author":"E Mroszczak","year":"1996","unstructured":"Mroszczak E, Combs D, Chaplin M, Tsina I, Tarnowski T, Rocha C, et al. Chiral Kinetics and Dynamics of Ketorolac. J Clin Pharmacol. 1996;36(6):521\u201339 [cited 2019 Feb 4]. Available from: https:\/\/accp1.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/j.1552-4604.1996.tb05042.x.","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"7716_CR29","first-page":"1288","volume":"288","author":"M-F Jett","year":"1999","unstructured":"Jett M-F, Ramesha CS, Brown CD, Chiu S, Emmett C, Voronin T, et al. Characterization of the Analgesic and Anti-Inflammatory Activities of Ketorolac and Its Enantiomers in the Rat. J Pharmacol Exp Ther. 1999;288(3):1288\u201397 [cited 2019 Feb 4]. Available from: http:\/\/jpet.aspetjournals.org\/content\/288\/3\/1288.","journal-title":"J Pharmacol Exp Ther"},{"issue":"12","key":"7716_CR30","doi-asserted-by":"publisher","first-page":"8531","DOI":"10.1074\/jbc.M112.435941","volume":"288","author":"L Hong","year":"2013","unstructured":"Hong L, Kenney SR, Phillips GK, Simpson D, Schroeder CE, N\u00f6th J, et al. Characterization of a Cdc42 Protein Inhibitor and Its Use as a Molecular Probe. J Biol Chem. 2013;288(12):8531\u201343 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3605667\/.","journal-title":"J Biol Chem"},{"issue":"2","key":"7716_CR31","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.ajpath.2017.10.018","volume":"188","author":"AS Peretti","year":"2018","unstructured":"Peretti AS, Dominguez D, Grimes MM, Hathaway HJ, Prossnitz ER, Rivera MR, et al. The R-Enantiomer of Ketorolac Delays Mammary Tumor Development in Mouse Mammary Tumor Virus-Polyoma Middle T Antigen (MMTV-PyMT) Mice. Am J Pathol. 2018;188(2):515\u201324 [cited 2018 Feb 12]. Available from: http:\/\/ajp.amjpathol.org\/article\/S0002-9440(17)30445-5\/abstract.","journal-title":"Am J Pathol"},{"issue":"1","key":"7716_CR32","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.taap.2012.01.025","volume":"260","author":"MK Walker","year":"2012","unstructured":"Walker MK, Boberg JR, Walsh MT, Wolf V, Trujillo A, Duke MS, et al. A less stressful alternative to oral gavage for pharmacological and toxicological studies in mice. Toxicol Appl Pharmacol. 2012;260(1):65\u20139 [cited 2019 Mar 7]. Available from: https:\/\/europepmc.org\/articles\/PMC3306547\/.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"4","key":"7716_CR33","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1258\/la.2012.012018","volume":"46","author":"A Corbett","year":"2012","unstructured":"Corbett A, McGowin A, Sieber S, Flannery T, Sibbitt B. A method for reliable voluntary oral administration of a fixed dosage (mg\/kg) of chronic daily medication to rats. Lab Anim. 2012;46(4):318\u201324 [cited 2019 Jul 24]. Available from. https:\/\/doi.org\/10.1258\/la.2012.012018.","journal-title":"Lab Anim"},{"issue":"3","key":"7716_CR34","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.2353\/ajpath.2010.100105","volume":"177","author":"E Lengyel","year":"2010","unstructured":"Lengyel E. Ovarian Cancer Development and Metastasis. Am J Pathol. 2010;177(3):1053\u201364 [cited 2019 Feb 1]. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0002944010601605.","journal-title":"Am J Pathol"},{"issue":"2","key":"7716_CR35","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/j.ab.2013.07.039","volume":"442","author":"T Buranda","year":"2013","unstructured":"Buranda T, BasuRay S, Swanson S, Agola J, Bondu V, Wandinger-Ness A. Rapid parallel flow cytometry assays of active GTPases using effector beads. Anal Biochem. 2013 Nov 15;442(2):149\u201357.","journal-title":"Anal Biochem"},{"issue":"1","key":"7716_CR36","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ymeth.2013.06.027","volume":"63","author":"MPA Davis","year":"2013","unstructured":"Davis MPA, van Dongen S, Abreu-Goodger C, Bartonicek N, Enright AJ. Kraken: A set of tools for quality control and analysis of high-throughput sequence data. Methods San Diego Calif. 2013;63(1):41\u20139 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3991327\/.","journal-title":"Methods San Diego Calif"},{"issue":"3","key":"7716_CR37","doi-asserted-by":"publisher","first-page":"R46","DOI":"10.1186\/gb-2014-15-3-r46","volume":"15","author":"DE Wood","year":"2014","unstructured":"Wood DE, Salzberg SL. Kraken: ultrafast metagenomic sequence classification using exact alignments. Genome Biol. 2014;15(3):R46 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4053813\/.","journal-title":"Genome Biol"},{"key":"7716_CR38","unstructured":"BBMap Guide. DOE Joint Genome Institute. [cited 2019 Nov 24]. Available from: https:\/\/jgi.doe.gov\/data-and-tools\/bbtools\/bb-tools-user-guide\/bbmap-guide\/."},{"issue":"2","key":"7716_CR39","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1093\/bioinformatics\/btu638","volume":"31","author":"S Anders","year":"2015","unstructured":"Anders S, Pyl PT, Huber W. HTSeq\u2014a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31(2):166\u20139 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4287950\/.","journal-title":"Bioinformatics"},{"issue":"1","key":"7716_CR40","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","volume":"26","author":"MD Robinson","year":"2010","unstructured":"Robinson MD, McCarthy DJ, Smyth GK. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010;26(1):139\u201340 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC2796818\/.","journal-title":"Bioinformatics"},{"key":"7716_CR41","volume-title":"Nondetects and Data Analysis for Environmental Data. R package version 1.6\u20131","author":"L Lopaka","year":"2017","unstructured":"Lopaka, Lee. Nondetects and Data Analysis for Environmental Data. R package version 1.6\u20131. 2017. Available from: https:\/\/CRAN.R-project.org\/package=NADA."},{"key":"7716_CR42","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3389\/fonc.2017.00024","volume":"7","author":"T Worzfeld","year":"2017","unstructured":"Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, et al. The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol. 2017;7:24.","journal-title":"Front Oncol"},{"issue":"11","key":"7716_CR43","doi-asserted-by":"publisher","first-page":"1498","DOI":"10.1038\/nm.2492","volume":"17","author":"KM Nieman","year":"2011","unstructured":"Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med. 2011;17(11):1498\u2013503 [cited 2019 Jan 17]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4157349\/.","journal-title":"Nat Med"},{"issue":"1","key":"7716_CR44","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12859-018-2353-5","volume":"19","author":"RJC Kluin","year":"2018","unstructured":"Kluin RJC, Kemper K, Kuilman T, de Ruiter JR, Iyer V, Forment JV, et al. XenofilteR: computational deconvolution of mouse and human reads in tumor xenograft sequence data. BMC Bioinformatics. 2018 Oct 4;19(1):366.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"7716_CR45","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1186\/s12920-019-0551-2","volume":"12","author":"XY Woo","year":"2019","unstructured":"Woo XY, Srivastava A, Graber JH, Yadav V, Sarsani VK, Simons A, et al. Genomic data analysis workflows for tumors from patient-derived xenografts (PDXs): challenges and guidelines. BMC Med Genomics. 2019;12(1):92.","journal-title":"BMC Med Genomics"},{"key":"7716_CR46","doi-asserted-by":"crossref","unstructured":"Ahdesm\u00e4ki MJ, Gray SR, Johnson JH, Lai Z. Disambiguate: An open-source application for disambiguating two species in next generation sequencing data from grafted samples. F1000Research. 2017;5 [cited 2019 Dec 26]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5130069\/.","DOI":"10.12688\/f1000research.10082.2"},{"key":"#cr-split#-7716_CR47.1","unstructured":"G\u00f6rg\u00fcl\u00fc K, Diakopoulos KN, Vatansever HS. A Star of Connection Between Pancreatic Cancer and Diabetes: Adrenomedullin. JOP J Pancreas. 2015;16"},{"key":"#cr-split#-7716_CR47.2","unstructured":"(5) [cited 2019 Mar 6]. Available from: http:\/\/pancreas.imedpub.com\/abstract\/a-star-of-connection-between-pancreatic-cancer-and-diabetesadrenomedullin-6908.html."},{"issue":"11","key":"7716_CR48","doi-asserted-by":"publisher","first-page":"e28222","DOI":"10.1371\/journal.pone.0028222","volume":"6","author":"LH Chen","year":"2011","unstructured":"Chen LH, Kuo W-H, Tsai M-H, Chen P-C, Hsiao CK, Chuang EY, et al. Identification of Prognostic Genes for Recurrent Risk Prediction in Triple Negative Breast Cancer Patients in Taiwan. PLOS ONE. 2011;6(11):e28222 [cited 2019 Mar 6]. Available from: https:\/\/journals.plos.org\/plosone\/article?id=10.1371\/journal.pone.0028222.","journal-title":"PLOS ONE"},{"issue":"1","key":"7716_CR49","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.canlet.2011.06.001","volume":"310","author":"J Cheng","year":"2011","unstructured":"Cheng J, Xie H-Y, Xu X, Wu J, Wei X, Su R, et al. NDRG1 as a biomarker for metastasis, recurrence and of poor prognosis in hepatocellular carcinoma. Cancer Lett. 2011;310(1):35\u201345 [cited 2019 Mar 6]. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0304383511003326.","journal-title":"Cancer Lett"},{"issue":"3","key":"7716_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1158\/1078-0432.CCR-13-1256","volume":"20","author":"D-J Cheon","year":"2014","unstructured":"Cheon D-J, Tong Y, Sim M-S, Dering J, Berel D, Cui X, et al. A collagen-remodeling gene signature regulated by TGF\u03b2 signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2014;20(3):711\u201323 [cited 2019 Mar 6]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3946428\/.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"2","key":"7716_CR51","doi-asserted-by":"publisher","first-page":"78","DOI":"10.4251\/wjgo.v9.i2.78","volume":"9","author":"GF do Esp\u00edrito Santo","year":"2017","unstructured":"do Esp\u00edrito Santo GF, Galera BB, Duarte EC, Chen ES, Azis L, Damazo AS, et al. Prognostic significance of vascular endothelial growth factor polymorphisms in colorectal cancer patients. World J Gastrointest Oncol. 2017;9(2):78\u201386 [cited 2019 Mar 6]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5314204\/.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"7716_CR52","doi-asserted-by":"publisher","first-page":"651","DOI":"10.21037\/tcr.2018.05.32","volume":"7","author":"Q Huang","year":"2018","unstructured":"Huang Q, Shen Z, Zang R, Fan X, Yang L, Xue M. Identification of novel genes and pathways in colorectal cancer exosomes: a bioinformatics study. Transl Cancer Res. 2018;7(3):651\u20138 [cited 2019 Mar 6]. Available from: http:\/\/tcr.amegroups.com\/article\/view\/21738.","journal-title":"Transl Cancer Res"},{"issue":"3","key":"7716_CR53","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1158\/2159-8290.CD-17-0284","volume":"8","author":"OMT Pearce","year":"2018","unstructured":"Pearce OMT, Delaine-Smith RM, Maniati E, Nichols S, Wang J, B\u00f6hm S, et al. Deconstruction of a Metastatic Tumor Microenvironment Reveals a Common Matrix Response in Human Cancers. Cancer Discov. 2018;8(3):304\u201319 [cited 2019 Mar 6]. Available from: http:\/\/cancerdiscovery.aacrjournals.org\/lookup\/doi\/10.1158\/2159-8290.CD-17-0284.","journal-title":"Cancer Discov"},{"issue":"10","key":"7716_CR54","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1111\/cas.12238","volume":"104","author":"A Sato-Tadano","year":"2013","unstructured":"Sato-Tadano A, Suzuki T, Amari M, Takagi K, Miki Y, Tamaki K, et al. Hexokinase II in breast carcinoma: A potent prognostic factor associated with hypoxia-inducible factor-1\u03b1 and Ki-67. Cancer Sci. 2013;104(10):1380\u20138 [cited 2019 Mar 6]. Available from: https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1111\/cas.12238.","journal-title":"Cancer Sci"},{"key":"7716_CR55","doi-asserted-by":"crossref","unstructured":"Shen J, Zhang Y, Yu H, Shen B, Liang Y, Jin R, et al. Role of DUSP1\/MKP1 in tumorigenesis, tumor progression and therapy. Cancer Med. 2016;5(8):2061\u20132068 [cited 2019 Feb 15]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4884638\/.","DOI":"10.1002\/cam4.772"},{"key":"7716_CR56","unstructured":"Sureshbabu A, Okajima H, Yamanaka D, Tonner E, Shastri S, Maycock J, et al. IGFBP5 induces cell adhesion, increases cell survival and inhibits cell migration in MCF-7 human breast cancer cells. J Cell Sci. 2012;(7):125, 1693\u20131705 [cited 2019 Mar 6]. Available from: http:\/\/jcs.biologists.org\/content\/125\/7\/1693."},{"issue":"4","key":"7716_CR57","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s10555-006-9037-8","volume":"25","author":"W-S Wu","year":"2006","unstructured":"Wu W-S. The signaling mechanism of ROS in tumor progression. Cancer Metastasis Rev. 2006 Dec;25(4):695\u2013705.","journal-title":"Cancer Metastasis Rev"},{"issue":"7","key":"7716_CR58","doi-asserted-by":"publisher","first-page":"5022","DOI":"10.18632\/oncotarget.3217","volume":"6","author":"H Zhao","year":"2014","unstructured":"Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B. CXCR4 over-expression and survival in cancer: A system review and meta-analysis. Oncotarget. 2014;6(7):5022\u201340 [cited 2019 Mar 6]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC4467131\/.","journal-title":"Oncotarget"},{"issue":"14","key":"7716_CR59","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.7150\/jca.24824","volume":"9","author":"S Lou","year":"2018","unstructured":"Lou S, Wang P, Yang J, Ma J, Liu C, Zhou M. Prognostic and Clinicopathological Value of Rac1 in Cancer Survival: Evidence from a Meta-Analysis. J Cancer. 2018;9(14):2571\u20139 [cited 2019 Feb 15]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6036885\/.","journal-title":"J Cancer"},{"key":"7716_CR60","doi-asserted-by":"crossref","unstructured":"Matondo A, Jo YH, Shahid M, Choi TG, Nguyen MN, Nguyen NNY, et al. The Prognostic 97 Chemoresponse Gene Signature in Ovarian Cancer. Sci Rep. 2017;7 [cited 2019 Jan 29]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5575202\/.","DOI":"10.1038\/s41598-017-08766-5"},{"key":"7716_CR61","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.2147\/OTT.S65373","volume":"7","author":"EI Braicu","year":"2014","unstructured":"Braicu EI, Luketina H, Richter R, Cacsire Castillo-Tong D, Lambrechts S, Mahner S, et al. HIF1\u03b1 is an independent prognostic factor for overall survival in advanced primary epithelial ovarian cancer - a study of the OVCAD consortium. OncoTargets Ther. 2014;7:1563\u20139.","journal-title":"OncoTargets Ther"},{"key":"7716_CR62","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1186\/1471-2407-14-696","volume":"14","author":"H Sallinen","year":"2014","unstructured":"Sallinen H, Heikura T, Koponen J, Kosma V-M, Heinonen S, Yl\u00e4-Herttuala S, et al. Serum angiopoietin-2 and soluble VEGFR-2 levels predict malignancy of ovarian neoplasm and poor prognosis in epithelial ovarian cancer. BMC Cancer. 2014 Sep 23;14:696.","journal-title":"BMC Cancer"},{"issue":"1","key":"7716_CR63","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13048-017-0323-6","volume":"10","author":"L Li","year":"2017","unstructured":"Li L, Cai S, Liu S, Feng H, Zhang J. Bioinformatics analysis to screen the key prognostic genes in ovarian cancer. J Ovarian Res. 2017 Apr 13;10(1):27.","journal-title":"J Ovarian Res"},{"issue":"3","key":"7716_CR64","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0092629","volume":"9","author":"C-F Liu","year":"2014","unstructured":"Liu C-F, Liu S-Y, Min X-Y, Ji Y-Y, Wang N, Liu D, et al. The prognostic value of CXCR4 in ovarian cancer: a meta-analysis. PLoS One. 2014;9(3):e92629.","journal-title":"PLoS One"},{"issue":"5","key":"7716_CR65","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1097\/PAI.0000000000000426","volume":"26","author":"AC Teixeira","year":"2018","unstructured":"Teixeira AC, Brasil IRC, Torres AFC, Tavora F. The evaluation of angiogenesis markers in hepatocellular carcinoma and precursor lesions in liver explants from a single institution. Appl Immunohistochem Mol Morphol AIMM. 2018;26(5):330\u20136.","journal-title":"Appl Immunohistochem Mol Morphol AIMM"},{"issue":"3","key":"7716_CR66","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.3892\/or.2013.2946","volume":"31","author":"D Wang","year":"2014","unstructured":"Wang D, Luo L, Chen W, Chen L-Z, Zeng W-T, Li W, et al. Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma. Oncol Rep. 2014 Mar;31(3):1199\u2013204.","journal-title":"Oncol Rep"},{"issue":"1","key":"7716_CR67","first-page":"48","volume":"58","author":"L Zhao","year":"2016","unstructured":"Zhao L, Zhang D, Ma H, Jin M, Huang F, Zhang T. High VEGF-A level at baseline predicts poor treatment effect of bevacizumab-based chemotherapy in metastatic colorectal cancer: a meta-analysis. Panminerva Med. 2016 Mar;58(1):48\u201358.","journal-title":"Panminerva Med"},{"issue":"7","key":"7716_CR68","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47.","journal-title":"Nucleic Acids Res"},{"issue":"9","key":"7716_CR69","doi-asserted-by":"publisher","first-page":"2127","DOI":"10.1158\/1078-0432.CCR-14-2279","volume":"21","author":"V Gonzalez-Villasana","year":"2015","unstructured":"Gonzalez-Villasana V, Fuentes-Mattei E, Ivan C, Dalton HJ, Rodriguez-Aguayo C, Fernandez-de Thomas RJ, et al. Rac1\/Pak1\/p38\/MMP-2 Axis regulates angiogenesis in Ovarian Cancer. Clin Cancer Res Off J Am Assoc Cancer Res. 2015;21(9):2127\u201337.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"37","key":"7716_CR70","doi-asserted-by":"publisher","first-page":"25150","DOI":"10.1074\/jbc.M800882200","volume":"283","author":"PJ Roberts","year":"2008","unstructured":"Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, et al. Rho Family GTPase modification and dependence on CAAX motif-signaled posttranslational modification. J Biol Chem. 2008;283(37):25150\u201363 [cited 2019 Mar 19]. Available from: http:\/\/europepmc.org\/abstract\/pmc\/pmc2533093.","journal-title":"J Biol Chem"},{"issue":"20","key":"7716_CR71","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.2174\/092986707781389600","volume":"14","author":"T Yuasa","year":"2007","unstructured":"Yuasa T, Kimura S, Ashihara E, Habuchi T, Maekawa T. Zoledronic acid - a multiplicity of anti-cancer action. Curr Med Chem. 2007;14(20):2126\u201335.","journal-title":"Curr Med Chem"},{"key":"7716_CR72","volume-title":"Toradol (Hoffman-La Roche Inc.): FDA Package Insert","author":"H-L Roche","year":"2009","unstructured":"Hoffman-La Roche. Toradol (Hoffman-La Roche Inc.): FDA Package Insert. 2009. Available from: https:\/\/druginserts.com\/lib\/rx\/meds\/toradol\/."},{"issue":"2S","key":"7716_CR73","doi-asserted-by":"publisher","first-page":"25S","DOI":"10.1002\/j.1552-4604.1998.tb04414.x","volume":"38","author":"DA Handley","year":"1998","unstructured":"Handley DA, Cervoni P, McCray JE, McCullough JR. Preclinical Enantioselective Pharmacology of (R)- and (S)- Ketorolac. J Clin Pharmacol. 1998;38(2S):25S\u201335S [cited 2019 Feb 4]. Available from: https:\/\/accp1.onlinelibrary.wiley.com\/doi\/abs\/10.1002\/j.1552-4604.1998.tb04414.x.","journal-title":"J Clin Pharmacol"},{"key":"7716_CR74","doi-asserted-by":"crossref","unstructured":"Russo R, De Caro C, Avallone B, Magliocca S, Nieddu M, Boatto G, et al. Ketogal: A Derivative Ketorolac Molecule with Minor Ulcerogenic and Renal Toxicity. Front Pharmacol. 2017;8 [cited 2019 Dec 26]. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5681857\/.","DOI":"10.3389\/fphar.2017.00757"},{"issue":"24","key":"7716_CR75","doi-asserted-by":"publisher","first-page":"5928","DOI":"10.1158\/1078-0432.CCR-10-1360","volume":"16","author":"X Lu","year":"2010","unstructured":"Lu X, Kang Y. Hypoxia and hypoxia-inducible factors: master regulators of metastasis. Clin Cancer Res Off J Am Assoc Cancer Res. 2010;16(24):5928\u201335 [cited 2019 Mar 19]. Available from: https:\/\/europepmc.org\/articles\/PMC3005023\/.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"4","key":"7716_CR76","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1007\/s10456-011-9229-x","volume":"14","author":"P Vader","year":"2011","unstructured":"Vader P, van der Meel R, Symons MH, Fens MHAM, Pieters E, Wilschut KJ, et al. Examining the role of Rac1 in tumor angiogenesis and growth: a clinically relevant RNAi-mediated approach. Angiogenesis. 2011;14(4):457\u201366.","journal-title":"Angiogenesis"},{"key":"7716_CR77","doi-asserted-by":"publisher","first-page":"i82","DOI":"10.1093\/bja\/aet464","volume":"113","author":"P Forget","year":"2014","unstructured":"Forget P, Bentin C, Machiels J-P, Berliere M, Coulie PG, De Kock M. Intraoperative use of ketorolac or diclofenac is associated with improved disease-free survival and overall survival in conservative breast cancer surgery. Br J Anaesth. 2014;113:i82\u20137 [cited 2019 Mar 19]. Available from: http:\/\/www.sciencedirect.com\/science\/article\/pii\/S0007091217306311.","journal-title":"Br J Anaesth"},{"issue":"2","key":"7716_CR78","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1007\/s10549-012-2094-5","volume":"134","author":"M Retsky","year":"2012","unstructured":"Retsky M, Rogers R, Demicheli R, Hrushesky WJ, Gukas I, Vaidya JS, et al. NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup. Breast Cancer Res Treat. 2012;134(2):881\u20138 [cited 2019 mar 19]. Available from. https:\/\/doi.org\/10.1007\/s10549-012-2094-5.","journal-title":"Breast Cancer Res Treat"},{"key":"7716_CR79","doi-asserted-by":"crossref","unstructured":"Retsky M, Demicheli R, Hrushesky WJM, Forget P, Kock MD, Gukas I, et al. Reduction of Breast Cancer Relapses with Perioperative Non-Steroidal Anti-Inflammatory Drugs: New Findings and a Review. Curr Med Chem. 2013; [cited 2019 Mar 19]. Available from: http:\/\/www.eurekaselect.com\/114602\/article.","DOI":"10.2174\/09298673113209990250"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07716-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-07716-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-07716-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,8]],"date-time":"2021-01-08T00:30:24Z","timestamp":1610065824000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-07716-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,7]]},"references-count":82,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["7716"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-07716-1","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,7]]},"assertion":[{"value":"7 February 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"<i>Foxn1<\/i><sup><i>nu<\/i><\/sup> NU \/J athymic nude mice (6\u20139\u2009weeks) were purchased from The Jackson Laboratory (Bar Harbor, ME, stock number 002019). For toxicity assessment studies at increased R-ketorolac dose, athymic nude mice were purchased from Charles River Laboratory (Wilmington, MA, strain code 490). Animals were housed according to treatment groups. Water and standard mouse chow were available ad libitum. These studies were performed under an approved Institutional Animal Care and Use Committee (IACUC) protocol (#18\u2013200772-HSC).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"AWN and LGH are inventors on US patent 9,125,899 for therapeutic uses of NSAID R-enantiomers. All other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"40"}}